Takeda inks deal worth $1.04B with Arrowhead for liver disease therapyCollaboration and Licensing Agreement • May 17th, 2021
Collaboration and licensing agreement for bone-protective compounds for treatment of rheumatoid arthritisCollaboration and Licensing Agreement • November 16th, 2022
n/d : royalties on future sales of any products that may result from the alliance upon successful launch and commercialisation
Collaboration and licensing agreement for NPT200-11Collaboration and Licensing Agreement • February 3rd, 2022
Neuropore Therapies has earned a milestone payment related to its collaboration with UCB and the evaluation of UCB0599 for the treatment of Parkinson’s Disease. UCB0599 is an orally administered small molecule alpha-synuclein misfolding inhibitor arising from a Collaboration and License Agreement entered into between Neuropore Therapies and UCB Biopharma on December 31, 2014.
ContractCollaboration and Licensing Agreement • February 22nd, 2012
Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.
Per-target agreement enables Ascidian to pursue additional internal and collaborative programs within neurology and other therapeutic areasCollaboration and Licensing Agreement • June 10th, 2024
Ascidian’s RNA exon editing platform is designed to advance the therapeutic possibilities of RNA medicine and treat diseases not addressed by today’s gene editing technologies. The company designs and develops RNA exon editing therapeutics that edit RNA exons at the kilobase scale.
Collaboration and licensing agreement for multi-drug resistant antibiotics (updated)Collaboration and Licensing Agreement • September 14th, 2021
Discuva Ltd, the antibiotics drug discovery and development company, announced that its collaboration with Roche, originally initiated in February 2014, has been extended to February 2018 under a new contract amendment.
COLLABORATION AND LICENSING AGREEMENT Between NEC Corporation and Stratus Technologies Bermuda Ltd. November 25, 2005Collaboration and Licensing Agreement • January 25th, 2011 • Stratus Technologies Bermuda Holdings Ltd. • Electronic computers • New York
This Collaboration and Licensing Agreement (“Agreement”) is made and entered into as of the 25th day of November 2005, (hereinafter “Effective Date”), by and between Stratus Technologies Bermuda Ltd., a Bermuda corporation with its principle place of business at Milner House, 18 Parliament Street, Hamilton HM 12, Bermuda (hereinafter “Stratus”), and NEC Corporation, a Japanese corporation, having its principle place of business at 7-1, Shiba 5-chome, Minato-ku, Tokyo 108-8001, Japan (hereinafter “NEC”).
Collaboration and licensing agreement for knowhowCollaboration and Licensing Agreement • August 29th, 2024
This collaboration and licensing agreement contemplates a period of collaboration over the next four years with fees being paid by Neovasc to Penn. Following the first commercial sale of the Tiara, Neovasc will pay a stepped royalty on Tiara revenues.
VISCHER ADVISED COMBIGENE IN ITS AGREEMENT WITH SPARK THERAPEUTICSCollaboration and Licensing Agreement • May 22nd, 2024
CombiGene and Spark Therapeutics, a member of the Roche Group and a fully integrated, commercial gene therapy company dedicated to the fight against genetic diseases, have entered into an exclusive collaboration and licensing agreement for CombiGene's CG01 project, a gene therapy for the treatment of drug-resistant focal epilepsy.
Zeelandia and InnoV join forces with the latest gluten-free solutions.Collaboration and Licensing Agreement • June 1st, 2022
Zeelandia and Ireland's InnoV have entered into an exclusive collaboration and licensing agreement in the field of gluten-free and other 'Free From' solutions with regard to the sustainability trends in the bakery market.
Collaboration and licensing agreement for therapies for amyotrophic lateral sclerosisCollaboration and Licensing Agreement • September 23rd, 2023
Verge Genomics announced a three-year collaboration with Eli Lilly to research and develop novel therapies for the treatment of amyotrophic lateral sclerosis.
PRESS RELEASECollaboration and Licensing Agreement • March 11th, 2024
• Single-target agreement focused on development of novel, small molecule agonists of GPR52 discovered by Sosei Heptares with the potential to simultaneously address positive, negative and cognitive symptoms of schizophrenia
DealdocCollaboration and Licensing Agreement • November 13th, 2020
Collaboration and licensing agreement for lipid nanoparticle delivery technology for use in primary hyperoxaluria type 1 development program
Boehringer Ingelheim and MiNA Therapeutics to Develop Novel Treatment Approaches for Fibrotic Liver DiseasesCollaboration and Licensing Agreement • October 20th, 2021
• Collaboration and licensing agreement focused on investigating up to three targets and has a potential transactional value of up to EUR 307 million, excluding royalties
Collaboration and licensing agreement for GalXC RNAi technology platform to progress new drug targetsCollaboration and Licensing Agreement • July 7th, 2024 • New York
This milestone triggers two single-digit multimillion-dollar milestone payments to Dicerna, which the Company expects to receive in the fourth quarter of 2021.
Alnylam and Arrowhead Form Collaboration and Licensing AgreementCollaboration and Licensing Agreement • November 7th, 2020
– Arrowhead Receives License from Alnylam to Develop RNAi Therapeutic Toward Hepatitis B Virus (HBV) – – Alnylam Gains Access to Arrowhead's Dynamic Polyconjugate (DPC) Delivery Technology for "Alnylam 5x15" Target –
AGREEMENT betweenCollaboration and Licensing Agreement • July 20th, 2000 • Gemini Genomics PLC • Services-commercial physical & biological research
Collaboration and licensing agreement for EPA-based drug products and indicationsCollaboration and Licensing Agreement • June 15th, 2024
The collaboration is focused on the development and commercialization of early-stage drug products and indications based on the omega-3 acid, EPA (eicosapentaenoic acid).
Collaboration and licensing agreement for TAVALISSE (fostamatinib disodium hexahydrate)Collaboration and Licensing Agreement • July 11th, 2024
Rigel Pharmaceuticals entered into an exclusive license and supply agreement with Kissei Pharmaceutical to develop and commercialize TAVALISSE in all current and potential indications in Japan, China, Taiwan and the Republic of Korea.
Collaboration and licensing agreement for PNT2003Collaboration and Licensing Agreement • August 25th, 2023 • Delaware
Lantheus Holdings and POINT Biopharma Global announced a set of strategic collaboration agreements in which Lantheus will license exclusive worldwide rights to POINT’s PNT2002 and PNT2003 product candidates.
